Background: In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre-and postoperatively to an already aggressive three-drug regimen. In a subgroup of patients, loco-regional treatment intensification was attempted by using the intraarterial route to give cisplatin.
Introduction
The addition of aggressive systemic chemotherapy to complete surgery has greatly improved survival for osteosarcoma patients [1, 2] , Response of the primary to preoperative chemotherapy soon emerged as an important risk factor for metastases [3] [4] [5] . Preliminary results reported for the Memorial Sloan-Kettering's T10 protocol suggested that postoperative salvage chemotherapy for poor responders might be feasible [6] . The co-operative German-Austrian-Swiss osteosarcoma study group COSS then undertook a randomised study, COSS-82, trying to spare some patients from the chronic toxicity of doxorubicin and cisplatin by using these only in case of poor response to a less aggressive preoperative regimen [7] . However, poor responders were not salvaged by postoperative intensification and, consequently, outcome was poor with this low-toxicity regimen [7] . Our conclusion was that osteosarcoma treatment should be as aggressive as possible upfront. This concept was realised in the follow-up study, COSS-86, where preoperative ifosfamide was added to an already aggressive threedrug regimen.
In addition to its association with a lower frequency of distant metastases, a good response to preoperative systemic chemotherapy also correlates with a reduced risk for local recurrence, particularly in patients with close resection margins [8, 9] . Therefore, a maximally tumoricidal loco-regional effect of chemotherapy is desired. For study COSS-86, it was decided to evaluate whether there was a benefit of using the intraarterial (i.a.) over the intravenous (i.v.) route to give cisplatin. COSS-80 [4] COSS-82 [7] (study arm) COSS-82 [7] Patients treated on protocol COSS-80 were given either cisplatin or BCD [4] . Patients treated on protocol COSS-82 received an alternate salvage regimen postoperatively in case of poor response to preoperative treatment [7] . BCD = bleomycin, cyclophosphamide, dactinomycin; doses as published [4, 7] .
Patients and methods

Patients
Study COSS-86 was open for enrolment from two of 86 to 11 of 88. Patients were eligible as study patients if they were 4 40 years of age and were registered within three weeks of biopsy of a primary, previously untreated high-grade central osteosarcoma of an extremity, were free of detectable metastases (including skip lesions) and had no unrelated ailment prohibiting chemotherapy. The diagnosis of osteosarcoma was established by clinical and X-ray findings and confirmed by open biopsy. The minimum requirements for exclusion of primary metastases were a negative chest X-ray and a negative 99 Tc-methylene diphosphonate (MDP) bone scan. The study protocol was accepted by the Protocol Review Committee of the Bundesministerium for Forschung und Technologie and the Ethics Committee at the Arztekammer Hamburg. Informed consent was obtained from all patients and/or their legal guardians, depending on the patient's age.
All patients fulfilling the entry criteria were included into analyses of overall and event-free survival on an intention-to-treat basis. Patients who were lost to follow-up were censored at time of last available information. The data on tumour response with COSS-86 have been published previously [10] . Therefore, the analysis of tumour response in this paper on survival was restricted to its evaluation as a risk-factor for survival. Response was assessed histologically using the criteria of Salzer-Kuntschik et al. [11] , with a good response defined as <10% viable tumour.
Treatment
A summary of the drugs used in the neoadjuvant COSS-protocols is given in Table 1 . Chemotherapy in study COSS-86 was as published previously [10] . In brief, patients were stratified into a high-and a lowrisk stratum. A tumour was considered low-risk only if none of three defined risk-factors -tumour length 5= 1 of 3 of the involved bone; % chondroid ground substance in the biopsy specimen [12] ; 0% reduction of early and/or late phase activity in sequential 99 Tc-MDP bone scans, performed as previously described [13, 14] 3, 4, 13, 14, 18, 19, 22, 23, 27, 28, 31, 32) . In case of poor response to preoperative three-drug treatment, postoperative therapy was as for high-risk patients, but the patients were still followed within the low-risk group.
Ifosfamide at 2 x 3 g/m 2 as one-hour infusions (on the two days prior to every cisplatin) and uromitexan uroprotection were added to the protocol for high-risk patients. Here, preoperative cisplatin was originally given at 150 mg/m 2 over just one hour. Due to severe ototoxicity, the infusion was prolonged to five hours in the i.v.-arm (two of 86), later, the dose was reduced to 120 mg/m 2 for all patients (12 of 87) [10] . The numbers of treatment cycles for high-risk patients were five each for doxorubicin (weeks 1,11, 20, 29, 38) and ifosfamide plus cisplatin (weeks 5, 8, 15, 24, 33) , and 14 for high-dose methotrexate (as above plus weeks 36, 37).
High-risk patients were to receive their preoperative cisplatin either i.v. or i.a. [10] . While originally designed as a randomised trial, this concept was abandoned in favour of central allocation at the end of 1987, due to low compliance with randomisation. This centralised allocation strove to balance patient age and sex, tumour site and size between the two cisplatin application arms. For the analyses of i.a. vs. i.v. cisplatin reported below, all high-risk patients who received at least one i.a. treatment were compared to those who received i.v. cisplatin only.
Definitive surgery was scheduled for week ten. Guidelines for hydration and other supportive measures were given in the protocol. Minimum required blood counts and other laboratory parameters for continuation of chemotherapy were specified. During therapy, toxicity monitoring was as previously reported [10] . Ototoxicity was searched for by audiograms and considered severe if a hearing aid was required or if hearing loss was > 30 dB at < 2 kHz. Echocardiograms were used to monitor cardiac function before doxorubicin, which was to be eliminated if signs suggesting cardiomyopathy developed. All cardiac malfunction severe enough to require medical intervention or to cause death was recorded. Only heart failure unrelated to systemic infection or terminal cancer was considered anthracycline related.
Statistical analysis
Survival analyses were performed using the Kaplan-Meier method [15] . The log-rank test was used to compare actuarial survival probabilities [16] . The chi 2 -test was used to compare unrelated samples. All P-values are two sided and significant indicates P < 0.05.
Results
One hundred seventy-one osteosarcoma patients from 49 participating institutions (see Appendix) fulfilled all entry criteria. Pathology review by a member of the COSS pathology panel was performed for 141. The search for primary pulmonary metastases reportedly included X-ray plus CT-scan in 127 of 171 (74%) and X-ray only in 24 (14%) (method not documented in 20 (12%)). Median follow-up was 8.35 years for all patients and 9.46 years for surviving patients. The number of patients reported here differs from that in our previous report on histologic tumour-response [10] because patients with primary metastases, delayed start of chemotherapy, or axial primaries were included in the former report, but were not eligible for the regular study for survival analyses.
Survival
For the group of 171 patients, actuarial overall and event-free survival at ten years was 72% and 66%, respectively ( Figure 1 , Table 2 ). Only tumour response to preoperative chemotherapy correlated significantly with both overall and event-free survival, while tumour size correlated significantly with event-free survival (Table 2) . Seven patients died of treatment related complications, all without ever relapsing (see below). Forty-two patients developed distant metastases as first adverse event, of these, 34 had died at last follow-up. Two patients (1.2%) died before definitive surgery and definitive surgery was refused in favour of irradiation in another four, who all relapsed locally. Altogether, ten patients developed a local recurrence, seven as first and the other three as second or later relapse. The local failure rate for operated tumours was 3.6% (six of 165). Only two of ten patients survived following local failure. One of these had received a secondary amputation following irradiation when a scheduled re-biopsy revealed renewed tumour growth, before clinical evidence of relapse. The other patient was alive 2+ months following an unusually late local relapse 102 months after diagnosis. Ablative surgery (amputation, disarticulation, rotation plasty) was used more frequently (96, 56.1%) than limb-salvage surgery (69, 40.4%). The choice of surgical procedure did not correlate with prognosis ( Table 2) . Three of six patients with local relapse after definitive surgery had had limb-salvage surgery, one Tumour response was related to overall survival {P = 0.0078, log-ranktest), tumour response (P = 0.0042) and tumour size (P = 0.019) to event-free survival. All other P-values > 0.05.
each had been amputated, disarticulated, and treated with a rotation plasty. As for risk stratification, 128 of 171 patients were stratified as high-risk and 41 as low-risk, two were not stratified (one died prior to stratification, another received preoperative therapy according to a different protocol). Prognosis did not differ significantly between the two risk groups (Table 2) . Fifty-six of 128 high-risk patients received at least one preoperative cisplatin intraarterially. The distribution of risk factors between these patients and those given intravenous therapy only was even, except that, among those who were operated, limb-salvage surgery was used more often after intraarterial treatment (P = 0.007). No significant correlation between cisplatin route and survival was detected (Table 3) . Considering only those 124 of 128 high-risk patients who went on to definitive surgery, local recurrence developed in three of 68 patients in the i.v. group and zero of 56 in the i.a. group (plus three in the low-risk stratum). 
75% (SE 5%) 67% (SE 7%)
Limb salvage surgery was used more often in the l.a. group (P = 0.007, X 2 ), the distribution of all other variables did not differ significantly (P > 0.05).
Toxicity of chemotherapy
Treatment related mortality Overall treatment related mortality was 4.1% (seven of 171). Four patients succumbed to acute toxicity (one each gastrointestinal and intracranial haemorrhage, one cardiomyopathy, one bacterial myocarditis). Three further patients succumbed to late toxic effects. Two of these died from anthracycline cardiomyopathy 22 and 39 months off therapy. (Two additional patients underwent heart transplants at 96 and 104 months, respectively; four further patients required medication to treat cardiac malfunction.) The third patient developed an acute leukaemia and died four years after therapy.
Toxicity associated with ifosfamide/'cisplatin
Acute toxicities (myelotoxicity, gastrointestinal upset) were considerable, but manageable, as reported previously [11] . Data on ototoxicity was available for 154 of 171 patients. Severe ototoxicity as denned developed in 26 of 154 (16.9%). Six patients required a hearing aid, four of whom had received cisplatin at 150 mg/m 2 over one hour (Table 4) . Two patients developed acute renal failure. One received his first cisplatin at 120 mg/m 2 over one hour i.v. and then required dialysis for seven days, the second developed a serum creatinine of 7 mg/dl after the first ifosfamide/cisplatin course (120 mg/m 2 ). Renal function improved in both and they went on to receive chemotherapy without cisplatin or ifosfamide. Terminal renal failure requiring dialysis developed in two other patients several years after seemingly uneventful chemotherapy.
Discussion
Doxorubicin and high-dose methotrexate were the first agents with proven activity against osteosarcoma [17] [18] [19] . In the late 1970s, cisplatin was introduced as the third active drug [20] . Since then, most protocols have relied on varying combinations of the aforementioned agents [2] . While some have claimed success for bleomycin with cyclophosphamide and dactinomycin (BCD) [21] , this could not be confirmed by others [22] . Using the agents described above in study COSS-80 and the aggressive control arm of study COSS-82, our group has achieved long term disease-free survival in well over half of those patients who presented with localised extremity osteosarcoma [4, 7] . It must be taken into account that these results were reached within a truly multicenter setting, with a score of participating hospitals from three countries. On a nation-wide basis -judging from German Paediatric Cancer Registry data -the percentage of targeted patients in the paediatric age group who were accrued for these studies was consistently above 75% [23] .
While these COSS results were at least comparable to those of other contemporary large multicenter trials [1, 2, [24] [25] [26] , secondary metastases still presented a serious problem. In study COSS-86, an attempt was made to intensify systemic treatment. Ifosfamide, of all available agents, seemed to offer the most promise [27] [28] [29] . It was decided to add the drug as the fourth active agent to an already aggressive regimen consisting of doxorubicin, high-dose methotrexate, and cisplatin. As our study COSS-82 had failed to find any benefit of postoperative salvage therapy [7] , late intensification did not appear promising. Therefore, ifosfamide was introduced upfront, starting during the preoperative phase of chemotherapy, for all but a small, select group of patients believed to be at low risk for relapse. We have previously reported that the response rate with this COSS-86 regi-men, the most aggressive therapy ever used by our group, was the highest we ever achieved [10] . Now, after a very long follow-up of almost ten years, overall-and disease free-survival have reached plateaus at 72% and 66%, respectively, and this with all eligible patients included on an intention-to-treat basis. These results suggest that, even in multicenter settings, approximately two thirds of children and adults not older than 40 years with localised osteosarcoma of the limbs can be cured by an approach encompassing complete surgery and aggressive chemotherapy.
To our knowledge, this is the first report on long-term follow-up for a large group of patients receiving preoperative and postoperative ifosfamide as part of polychemotherapy for osteosarcoma. It will be interesting to learn if results similar to those of COSS-86 will be observed in the randomised trial currently being performed by the Childrens Cancer Group and the Pediatric Oncology Group, where the same four agents doxorubicin, high-dose methotrexate, cisplatin and ifosfamide are used in one of the arms [30] .
Unexpectedly, the COSS-86 'low-risk' group did not have a better outcome than the high-risk group. Obviously, the risk factors used were not sufficient to predict treatment success. For one, the relative measure of tumour size used (^ 1/3 vs. <l/3 of the involved bone) was not as distinctive as absolute measures seem to be [31, 32] . Also, while quite reliable when performed immediately prior to surgery, the scintigraphic tumour/ non-tumour technique used to predict tumour response is probably inferior to more sophisticated methods when used at earlier points of preoperative treatment [14] , Determining the amount of chondroid in the tumour biopsy specimen did not add to clarity in this study. Still, the three parameters as used were able to define a group of patients which achieved the same good results with three drugs as the rest did with four. If the good results achieved for high-risk patients were due to ifosfamide, then treatment success for low-risk patients might have been even better if it would not have been withheld from their treatment. The trial design does not allow us to exclude the possibility that, alternatively, the prognostic factors used -which were derived from the experience obtained with earlier COSS studies -could have completely failed to discriminate between risk groups in the setting of the present protocol. In this case, the lack of difference in outcome between the strata would not have been due to ifosfamide, but rather to other differences between COSS-86 and prior COSS-protocols (as detailed in Table 1 ), which would have alleviated the prognostic differences previously observed.
Intraarterial chemotherapy has been proposed as loco-regional treatment intensification [33] . Applying cisplatin intraarterially did not influence tumour response favourably in our aggressive COSS-86 combination chemotherapy protocol [10] . Due to the locoregional nature of intraarterial therapy, systemic benefits had not been expected to begin with. If anything, survival data were slightly poorer for patients treated intraarterially, but the difference did not reach statistical significance. As plasma platinum levels were virtually identical regardless of vascular access [34] , systemic activity of cisplatin should not have been compromised by intraarterial application. More likely, a selection bias was introduced despite the efforts of the study centre to obtain balanced groups.
While being highly effective, the COSS-86 regimen was also rather toxic. We have previously reported significant myelotoxicity for the ifosfamide/cisplatincombination [10] . The untoward effect which was most dramatically increased compared to our prior experience was hearing loss. One quarter of those patients who received any cisplatin at 150 mg/m 2 over just one hour developed severe hearing loss. While the influence of the drug's peak levels on ototoxicity is well known [35] , such a devastating effect of giving a maximum of only two out of five courses at an increased dose rate came as a surprise. From our data, it seems that the dose increase from 120 to 150 mg/m 2 might have been more important than the reduced infusion time. Too few patients received therapy without ifosfamide in order to prove or exclude the proposed enhancing effect [36] of this drug on cisplatin induced hearing loss.
In contrast to severe ototoxicity, severe nephrotoxicity was only rarely observed. The exact cause of chronic renal failure developing years after the end of chemotherapy in two patients remains obscure, but a correlation to therapy related damage is quite possible [37] . In recent years, there has been growing concern about ifosfamide's renal-tubular toxicity. This problem was not assessed prospectively in our study. Judging from detailed analyses of paediatric patients [38] [39] [40] , it seems that the relatively low cumulative dose used here (max. 30 g/m 2 ) should only rarely cause a Fanconi syndrome.
As in many other osteosarcoma trials, anthracycline cardiotoxicity was the most worrisome side effect. Three patients died as a consequence of anthracycline cardiomyopathy, two further patients required heart-transplants, and this even though cumulative doxorubicin did not exceed the proposedly relatively 'safe' 450 mg/m 2 . Taking into account the high incidence of subclinical damage and the well known tendency for continued deterioration [41] [42] [43] , additional cases of late cardiac failure must be feared for in the future.
Altogether, aggressive combination chemotherapy according to COSS-86 led to long-term disease-free survival in approximately two thirds of young patients with localised extremity osteosarcoma, albeit at the cost of significant early and late toxicity. Future COSS-trials will try to reproduce the good oncologic results with fewer untoward effects.
